Sinopec Capital and Meinian Onehealth both invested in the biotech research product maker as it prepares for an initial public offering.
China-based life sciences product developer CapitalBio Technology has raised more than RMB800m ($113m) from investors including oil and gas supplier Sinopec and healthcare services provider Meinian Onehealth, DealStreetAsia reported yesterday.
Guangzhou Boyi Architectural Design Institute put up $57m to lead the round, which also featured New Alliance Capital, Red Horse Investments Group, Xin Dig Capital and Friend Capital, while Sinopec’s contribution came from investment vehicle Sinopec Capital.
Founded in 2012 as a subsidiary of medical technology producer CapitalBio Corporation, CapitalBio…
